By Nick Johnson (Apyx) In 2023 Shareholder News, J-Plasma, RenuvionPosted April 5, 2023APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON MAY 11, 2023 READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted March 27, 2023RENUVION WINS ADDY AWARD FOR #THISISME CAMPAIGN READ MORE
By apyxmedical In 2023 Shareholder News, J-Plasma, RenuvionPosted March 16, 2023APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2023 FINANCIAL OUTLOOK READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted February 27, 2023APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO COAGULATE AND CONTRACT SOFT TISSUES, INCLUDING SUBCUTANEOUS TISSUE, WHERE NEEDED READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, J-Plasma, RenuvionPosted February 21, 2023APYX MEDICAL CORPORATION ANNOUNCES NEW FIVE-YEAR CREDIT AGREEMENT WITH MIDCAP FINANCIAL READ MORE
By apyxmedical In 2023 Shareholder News, J-Plasma, RenuvionPosted February 16, 2023APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS ON MARCH 16, 2023 READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted February 9, 2023RENUVION COSMETIC NECK LAXITY PROCEDURE TO BE FEATURED ON ‘THE BALANCING ACT’ TALK SHOW ON LIFETIME FEBRUARY 13 READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted February 1, 2023APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION FOR THE USE OF THE RENUVION APR HANDPIECE FOR THE COAGULATION OF SUBCUTANEOUS SOFT TISSUES WHERE NEEDED, FOLLOWING LIPOSUCTION READ MORE
By apyxmedical In 2023 Shareholder News, RenuvionPosted January 25, 2023APYX MEDICAL CORPORATION LAUNCHES NEW ‘APYX ONE CONSOLE’ FOR COSMETIC SURGICAL PROCEDURES IN THE UNITED STATES READ MORE
By apyxmedical In 2023 Shareholder News, J-Plasma, RenuvionPosted January 10, 2023APYX MEDICAL CORPORATION REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 REVENUE RESULTS READ MORE